Total Payments
$59,747
2022 Payments
$105.24
Companies
7
Transactions
95
Medicare Patients
1,667
Medicare Billing
$214,996
Payment Breakdown by Category
Consulting$40,513 (67.8%)
Other$8,975 (15.0%)
Travel$8,027 (13.4%)
Food & Beverage$2,233 (3.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $40,513 | 11 | 67.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,975 | 3 | 15.0% |
| Travel and Lodging | $8,027 | 39 | 13.4% |
| Food and Beverage | $2,233 | 42 | 3.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $26,410 | 35 | $0 (2017) |
| AbbVie, Inc. | $20,494 | 42 | $0 (2017) |
| Mallinckrodt Enterprises LLC | $7,254 | 4 | $0 (2019) |
| Gilead Sciences, Inc. | $5,114 | 9 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $350.00 | 1 | $0 (2021) |
| UCB, Inc. | $105.24 | 3 | $0 (2022) |
| OPKO Pharmaceuticals, LLC | $20.79 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $105.24 | 3 | UCB, Inc. ($105.24) |
| 2021 | $350.00 | 1 | SANOFI-AVENTIS U.S. LLC ($350.00) |
| 2020 | $20.79 | 1 | OPKO Pharmaceuticals, LLC ($20.79) |
| 2019 | $11,995 | 11 | Mallinckrodt Enterprises LLC ($6,881) |
| 2018 | $372.22 | 2 | Mallinckrodt LLC ($372.22) |
| 2017 | $46,904 | 77 | Merck Sharp & Dohme Corporation ($26,410) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/14/2022 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $30.43 | General |
| Category: Neurology | ||||||
| 04/12/2022 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $38.16 | General |
| Category: Neurology | ||||||
| 03/15/2022 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $36.65 | General |
| Category: Neurology | ||||||
| 03/22/2021 | SANOFI-AVENTIS U.S. LLC | LEMTRADA (Biological), THYMOGLOBULIN | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $350.00 | General |
| Category: Neurology | ||||||
| 01/27/2020 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Hyperparathyroidism | ||||||
| 03/29/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $395.60 | General |
| Category: HBV | ||||||
| 03/29/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $346.61 | General |
| Category: HBV | ||||||
| 03/29/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $136.09 | General |
| Category: HBV | ||||||
| 03/29/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $51.64 | General |
| Category: HBV | ||||||
| 03/29/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: HBV | ||||||
| 03/29/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: HBV | ||||||
| 03/29/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: HBV | ||||||
| 03/29/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $34.00 | General |
| Category: HBV | ||||||
| 03/20/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: HBV | ||||||
| 01/02/2019 | Mallinckrodt Enterprises LLC | UVADEX (Drug) | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| Category: CRITICAL CARE | ||||||
| 01/02/2019 | Mallinckrodt Enterprises LLC | UVADEX (Drug) | Travel and Lodging | Cash or cash equivalent | $381.40 | General |
| Category: CRITICAL CARE | ||||||
| 12/15/2018 | Mallinckrodt LLC | UVADEX METHOXSALEN STERILE SOLUTION (Drug) | Food and Beverage | In-kind items and services | $244.25 | General |
| Category: CRITICAL CARE | ||||||
| 12/15/2018 | Mallinckrodt LLC | UVADEX METHOXSALEN STERILE SOLUTION (Drug) | Travel and Lodging | In-kind items and services | $127.97 | General |
| Category: CRITICAL CARE | ||||||
| 12/19/2017 | AbbVie, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| 12/19/2017 | AbbVie, Inc. | — | Travel and Lodging | In-kind items and services | $51.00 | General |
| 12/02/2017 | AbbVie, Inc. | — | Travel and Lodging | In-kind items and services | $687.40 | General |
| 12/02/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $65.00 | General |
| 12/02/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $44.99 | General |
| 12/02/2017 | AbbVie, Inc. | — | Travel and Lodging | In-kind items and services | $30.77 | General |
| 12/02/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 307 | 479 | $159,117 | $36,995 |
| 2022 | 6 | 360 | 676 | $219,135 | $48,148 |
| 2021 | 6 | 417 | 717 | $222,204 | $51,914 |
| 2020 | 6 | 583 | 1,139 | $316,496 | $77,938 |
Total Patients
1,667
Total Services
3,011
Medicare Billing
$214,996
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 83 | 230 | $63,480 | $15,487 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 99 | 117 | $34,983 | $8,734 | 25.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 69 | 71 | $30,459 | $8,262 | 27.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 56 | 61 | $30,195 | $4,512 | 14.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 115 | 398 | $109,848 | $24,329 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 85 | 108 | $32,292 | $8,289 | 25.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 85 | 87 | $43,065 | $6,822 | 15.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 46 | 47 | $20,163 | $5,660 | 28.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 15 | $7,950 | $1,762 | 22.2% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Facility | 2022 | 16 | 21 | $5,817 | $1,287 | 22.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 132 | 400 | $110,400 | $24,867 | 22.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 112 | 122 | $46,140 | $10,109 | 21.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 113 | 129 | $38,571 | $10,105 | 26.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 33 | 33 | $14,157 | $4,126 | 29.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 15 | $7,950 | $1,638 | 20.6% |
| 99225 | Subsequent observation care, typically 25 minutes per day | Facility | 2021 | 12 | 18 | $4,986 | $1,067 | 21.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 214 | 720 | $198,711 | $45,930 | 23.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 187 | 206 | $61,594 | $14,351 | 23.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 105 | 112 | $13,440 | $7,750 | 57.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 40 | 42 | $22,260 | $5,180 | 23.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 20 | 34 | $13,566 | $3,118 | 23.0% |
| 99225 | Subsequent observation care, typically 25 minutes per day | Facility | 2020 | 17 | 25 | $6,925 | $1,609 | 23.2% |
About Dr. David Roth, MD
Dr. David Roth, MD is a Nephrology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023033925.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Roth, MD has received a total of $59,747 in payments from pharmaceutical and medical device companies, with $105.24 received in 2022. These payments were reported across 95 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($40,513).
As a Medicare-enrolled provider, Roth has provided services to 1,667 Medicare beneficiaries, totaling 3,011 services with total Medicare billing of $214,996. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Miami, FL
- Active Since 07/12/2006
- Last Updated 01/24/2014
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1023033925
Products in Payments
- Viekira (Drug) $10,722
- UVADEX (Drug) $6,881
- Vemlidy (Drug) $5,114
- ZEPATIER (Drug) $2,838
- UVADEX METHOXSALEN STERILE SOLUTION (Drug) $372.22
- LEMTRADA (Biological) $350.00
- Briviact (Drug) $105.24
- RAYALDEE (Drug) $20.79
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Miami
Murray Epstein, Md, MD
Nephrology — Payments: $447,823
Nephrology $447,823
Gabriel Contreras, Md, Mph, MD, MPH
Nephrology — Payments: $207,450
Nephrology $207,450
Alessia Fornoni, Md, Phd, MD, PHD
Nephrology — Payments: $80,140
Nephrology $80,140
Dr. Jonathan Da Costa, M.d, M.D
Nephrology — Payments: $45,108
Nephrology $45,108
Jorge Busse, Md, MD
Nephrology — Payments: $42,367
Nephrology $42,367
Loay Salman, Md, MD
Nephrology — Payments: $41,036
Nephrology $41,036